152 related articles for article (PubMed ID: 35197558)
21. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
22. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Enei Y; Atsuta M; Mori K; Obayashi K; Yoshihara K; Kondo Y; Oguchi T; Sadakane I; Habuchi T; Ohyama C; Shariat SF; Egawa S
Prostate; 2022 Oct; 82(14):1322-1330. PubMed ID: 35767376
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
24. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M
Cancer Med; 2016 Feb; 5(2):182-91. PubMed ID: 26710718
[TBL] [Abstract][Full Text] [Related]
25. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
26. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer.
Isaksson J; Green H; Papantoniou D; Pettersson L; Anden M; Rosell J; Åvall-Lundqvist E; Elander NO
World J Clin Oncol; 2021 Nov; 12(11):1009-1022. PubMed ID: 34909396
[TBL] [Abstract][Full Text] [Related]
27. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
28. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
29. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
30. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.
Maia MC; Pereira AAL; Lage LV; Fraile NM; Vaisberg VV; Kudo G; Barroso-Sousa R; Bastos DA; Dzik C
J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241182
[TBL] [Abstract][Full Text] [Related]
32. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
33. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Vestris PG; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2022 Feb; 82(2):269-275. PubMed ID: 34822183
[TBL] [Abstract][Full Text] [Related]
34. Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Peltekian S; Sajwani S; Wang X; Kanji S
Support Care Cancer; 2023 May; 31(5):311. PubMed ID: 37126153
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
Wenzel M; Borkowetz A; Lieb V; Hoffmann MA; Borgmann H; Höfner T; Dotzauer R; Neuberger M; Worst TS; von Hardenberg J; Linxweiler J; Klümper N
Urol Oncol; 2022 Dec; 40(12):538.e7-538.e14. PubMed ID: 36244915
[TBL] [Abstract][Full Text] [Related]
36. Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.
Thurin NH; Rouyer M; Jové J; Gross-Goupil M; Haaser T; Rébillard X; Soulié M; de Pouvourville G; Capone C; Bazil ML; Messaoudi F; Lamarque S; Bignon E; Droz-Perroteau C; Moore N; Blin P
Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1139-1145. PubMed ID: 35984212
[TBL] [Abstract][Full Text] [Related]
37. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Galli L; Chiuri VE; Di Lorenzo G; Pisconti S; Rossetti S; Sirotova Z; Muto A; Petrioli R; De Tursi M; Sbrana A; Francolini G; Ardizzoia A; Scavelli C; Satta F; Quadrini S; Airoldi M; D'Aniello C; Bonetti A; Conforti S; Aieta M; Beccaglia P; Maestri A; Fratino L
Tumori; 2023 Apr; 109(2):224-232. PubMed ID: 35400269
[TBL] [Abstract][Full Text] [Related]
38. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A; Anton A; Shapiro J; Wong S; Azad A; Kwan E; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua AM; Pook D; Gibbs P; Tran B; Weickhardt A
Asia Pac J Clin Oncol; 2021 Feb; 17(1):36-42. PubMed ID: 32970925
[TBL] [Abstract][Full Text] [Related]
39. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
40. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]